K K Herfarth1, J Debus, F Lohr, M L Bahner, M Wannenmacher. 1. Klinische Kooperationseinheit Strahlentherapeutische Onkologie, Deutsches Krebsforschungszentrum, Abt. E0500, Im Neuenheimer Feld 280, 69120 Heidelberg. klaus@herfarth.de
Abstract
PURPOSE: A number of minimal-invasive methods have been developed for the treatment of non-resectable liver metastases. A focused high dose can be delivered to a liver tumor with sparing of surrounding normal liver tissue using non-invasive stereotactic techniques. METHODS: Sixty-six metastases were treated stereotactically in 43 patients during a phase 2 trial. RESULTS: There were no major side effects observed. The actuarial local control was 82% after 18 months. The median actuarial survival was 24 months. However, there was a significantly improved survival in patients without additional extrahepatic tumor manifestation at the time of treatment compared to those, who were treated in palliative intention (87% vs. 24% after 18 months, p = 0.001 (log-rank). CONCLUSION: Stereotactic single dose irradiation is a non-invasive and safe treatment option for patients with inoperable liver metastases. Phase III studies will further evaluate this new approach.
PURPOSE: A number of minimal-invasive methods have been developed for the treatment of non-resectable liver metastases. A focused high dose can be delivered to a liver tumor with sparing of surrounding normal liver tissue using non-invasive stereotactic techniques. METHODS: Sixty-six metastases were treated stereotactically in 43 patients during a phase 2 trial. RESULTS: There were no major side effects observed. The actuarial local control was 82% after 18 months. The median actuarial survival was 24 months. However, there was a significantly improved survival in patients without additional extrahepatic tumor manifestation at the time of treatment compared to those, who were treated in palliative intention (87% vs. 24% after 18 months, p = 0.001 (log-rank). CONCLUSION: Stereotactic single dose irradiation is a non-invasive and safe treatment option for patients with inoperable liver metastases. Phase III studies will further evaluate this new approach.
Authors: Florian Sterzing; Thomas B Brunner; Iris Ernst; Wolfgang W Baus; Burkhard Greve; Klaus Herfarth; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2014-08-05 Impact factor: 3.621
Authors: Birgitt van Oorschot; Gabriele Beckmann; Wolfgang Schulze; Dirk Rades; Petra Feyer Journal: Breast Care (Basel) Date: 2011-02-14 Impact factor: 2.860